Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | CIT | O14578 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888204 | 0.89 | EPHX2 (0.48) | SMN1; SMN2ALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL4886597 | 0.85 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL23747460 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2ALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL5523975 | 0.83 | ALDH1A1 (0.75) | SMN1; SMN2ALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL26100647 | 0.82 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL26097960 | 0.81 | ALDH1A1 (0.65) | SMN1; SMN2ALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL23728220 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL26102262 | 0.80 | ALDH1A1 (0.67) | SMN1; SMN2ALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL23747554 | 0.78 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL26102668 | 0.78 | ALDH1A1 (0.67) | SMN1; SMN2ALDH1A1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | SMN1; SMN2 3140/4885ALDH1A1 1732/4885NPC1 83/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | SMN1; SMN2 1943/4885ALDH1A1 2546/4885NPC1 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.